Big Picture Medicine cover art

Big Picture Medicine

Big Picture Medicine

Written by: Mustafa Sultan MD
Listen for free

The health entrepreneurship podcast — focusing on big picture stuff. Interviews with health/biotech entrepreneurs and leaders having impact at scale. Health stuff a techbro/sis would find interesting. Think health meets the Tim Ferriss Show. Get in touch: pod@musty.io451135 Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • #141 $1.1B exit... then a MedTech with 12mo of runway called — Joe DeVivo (Butterfly Network)

    #141 $1.1B exit... then a MedTech with 12mo of runway called — Joe DeVivo (Butterfly Network)
    May 27 2026

    Part 2 with Joe DeVivo, the MedTech CEO who sold InTouch to Teladoc for over $1B and promised himself never to do another turnaround.


    Two years later, the board of Butterfly Network called w/12mo cash left.


    Here's how he did it.
    Show More Show Less
    1 hr and 1 min
  • #140 Should the NHS Trigger the £330M Palantir Break Clause? An Insider's Take

    #140 Should the NHS Trigger the £330M Palantir Break Clause? An Insider's Take
    May 11 2026

    Tom Bartlett spent 22 years inside the NHS. For three and a half years, he led the 150-person engineering team at NHS England that built the £330M Federated Data Platform with Palantir.


    He left a month ago and he's the only insider speaking publicly about what the platform actually does, what it costs, and whether the NHS has any credible alternative.


    We cover the architecture, the cost, the CLOUD Act, the BMJ exposé, the conflicts of interest at Chelsea & Westminster, and whether ministers should trigger the break clause.
    Show More Show Less
    49 mins
  • 🔥News: The New Healthcare AI Broker, Palantir Under Fire and Big Tech's Drug Discovery Mirage

    🔥News: The New Healthcare AI Broker, Palantir Under Fire and Big Tech's Drug Discovery Mirage
    May 9 2026

    Jared Dashevsky, MD (Healthcare Huddle) and Ala Alenazi, PhD (Kinnevik) join Mustafa to discuss:

    1. The rise of the AI Broker (a middleman that's about to emerge)
    2. Palantir's £330M NHS break clause
    3. OpenAI as pharma. We also discuss why drug discovery needs a "Human Genome Project 2.0"
    Show More Show Less
    39 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet